Sequana Medical NV

Sequana Medical NV, based in Belgium, focuses on innovative medical solutions for fluid overload due to liver disease, heart failure, and cancer, providing patients with novel therapies to improve their health outcomes. Founded in 2006, Sequana Medical NV operates out of Ghent, Belgium. The company specializes in developing medical devices and therapies for managing fluid overload, particularly in patients who do not respond to conventional treatment options. In February 2019, Sequana Medical raised EUR 27.

5 million through an IPO, selling shares at EUR 8. 5 each. The company has had a total of 10 deals, with the most recent being on February 8, 2019. The current CEO is Ian Crosbie, alongside Noel Johnson.

Sequana Medical specializes in innovative solutions for fluid overload associated with liver disease, heart failure, and cancer. Their core offerings include the alfa pump® system and the Direct Sodium Removal (DSR®) therapy, designed to alleviate complications from drug-resistant fluid overload. The alfa pump® is a fully-implanted, wireless device that actively removes excess fluid from the abdominal cavity and pumps it into the bladder for natural elimination. This technology, which has received CE mark approval in Europe and FDA Breakthrough Device status in the United States, specifically targets patients whose conditions render standard diuretics ineffective.

The company focuses on markets in Europe and the United States, where their medical technologies aim to enhance patient quality of life and healthcare outcomes. In 2022, Sequana Medical reported a revenue of EUR 972,326. 50, with an EBITDA of EUR -29,277,663. 10.

The company's revenue generation model is built around the sale and deployment of its proprietary medical devices, focusing on hospitals and healthcare providers treating advanced liver disease and heart failure. Their business model typically involves direct sales to healthcare institutions, establishing B2B relationships with facilities that manage patients requiring specialized care. Sequana Medical plans to leverage its most recent funding of EUR 24. 00 mn towards expanding its market presence and developing new products.

The company is focused on releasing additional innovations in its therapeutic offerings to address unmet medical needs in fluid management. Moreover, Sequana Medical aims to penetrate new geographic markets, particularly in Europe and the United States, to enhance access to its therapies and improve patient outcomes.